Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States

Abstract Background Neoadjuvant chemotherapy (NACT) for the treatment of muscle-invasive bladder cancer (MIBC) remains underutilized in the United States despite evidence supporting its use. Objectives To examine the perioperative chemotherapy management of patients with MIBC by medical oncologists...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2014-07, Vol.32 (5), p.637-644
Main Authors: Apolo, Andrea B., M.D, Kim, Joseph W., M.D, Bochner, Bernard H., M.D, Steinberg, Seth M., Ph.D, Bajorin, Dean F., M.D, Kevin Kelly, Wm., D.O, Agarwal, Piyush K., M.D, Koppie, Theresa M., M.D, Kaag, Matthew G., M.D, Quinn, David I., M.B.B.S., Ph.D, Vogelzang, Nicholas J., M.D, Sridhar, Srikala S., M.D
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Chemotherapy, Adjuvant - utilization
Humans
Medical Oncology
Middle Aged
Muscles - pathology
Neoadjuvant Therapy - utilization
Neoplasm Invasiveness
Surveys and Questionnaires
United States
Urinary Bladder Neoplasms - pathology
Urinary Bladder Neoplasms - therapy
Urology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Neoadjuvant chemotherapy (NACT) for the treatment of muscle-invasive bladder cancer (MIBC) remains underutilized in the United States despite evidence supporting its use. Objectives To examine the perioperative chemotherapy management of patients with MIBC by medical oncologists (MedOncs) to move toward standardization of practice Participants and methods A 26-question survey was emailed to 92 MedOncs belonging to the Bladder Cancer Advocacy Network or the American Society of Clinical Oncology for completion from May to October 2011 Results A total of 83 MedOncs completed the survey: 52% were based in academic centers. Most referrals were from urologists (79%). NACT for treatment of MIBC and high-grade upper-tract urothelial carcinoma is offered by 80% and 46% of respondents, respectively. Adjuvant chemotherapy for treatment of MIBC and upper-tract urothelial carcinoma is offered by 46% and 42% of respondents, respectively. NACT was not offered by 49%, 29%, and 35% of respondents if Eastern Cooperative Oncology Group performance status was 3 or greater, if patients had T2 lesions without lymphovascular invasion, and if the glomerular filtration rate was
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2013.12.012